RVVTF REVIVE THERAPEUTICS LTD
- 0.021400
- +0.001150+5.68%
REVIVE THERAPEUTICS LTD News
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti
Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Provides Corporate Update
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Psychedelic Stocks Gain After FDA Priority Review for MDMA Therapy
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
Revive Therapeutics Announces Offering of up to $3 Million
Revive Says Phase 3 Trial for Oral COVID Drug Failed
Revive Therapeutics Spikes After Update on Oral COVID-19 Drug
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin
FDA Asks Revive to Amend Main Goals of Phase 3 Trial for COVID Drug
Revive Therapeutics to Submit Updated Information for Phase 3 COVID Drug Trial Endpoints
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
Life sciences company Revive Therapeutics Ltd. (OTCQB:RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction. The company closed a private placement deal — with
Revive Therapeutics Raises $4.3M From Private Placement
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Life sciences biotech Psyence Group Inc. (OTCQB:PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). The company issued more than 7.
Revive Therapeutics To Raise Up To $5M Via Private Placement
REVIVE THERAPEUTICS LTD. (OTCQB:RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. The offerin
Psychedelic Stock Gainers And Losers From November 30, 2022
GAINERS:ATAI Life Sciences (NASDAQ:ATAI) shares closed up 11.71% at $3.53Compass Pathways (NASDAQ:CMPS) shares closed up 7.63% at $10.30Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.28% at $0.8
Analysis
Price Target
No Data
